Cabozantinib

DB08875ApprovedInvestigationalSmall moleculeKinase Inhibitor

Cabozantinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

Chemical structure of Cabozantinib
Mechanism
Curator reviewed · 1 reference
Primary indication
Cabozantinib, marketed under the brand name Cometriq, is indicated for the treatment of progressive, metastatic medullary thyroid cancer (MTC).Curator reviewed · 16 structured indications
Formula / weight
C28H24FN3O5 · 501.514 g/mol (avg)
First approval
Canada, 2018 · United States, 2012 · European Union, 2016
Code names
BMS-907351 · XL-184
Brand names
  • Cabometyx
  • Cometriq

Resolves to

Structure
InChIKeyONIQOQHATWINJY-UHFFFAOYSA-NSMILESCOC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2

What you can answer from here — as of September 13, 2026

13Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
522Drug interactionsStructured to mechanism, not free text
Sign in
253Clinical trialsPhase, status and sponsor resolved per trial
Sign in
16Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
47Marketed productsAcross 7 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 20 drug categories
Sign in
38+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Cabozantinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account